Collectively, these findings suggest that CK18 may serve as a promising biomarker reflecting disease activity and hepatic injury status in NAFLD and NASH, while also implicating a potential mechanistic link between hepatocyte apoptosis and cardiovascular involvement in this metabolic disorder. This evidence concerns the gene KRT18 and metabolic disease.